Indiana is currently home to 1210 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Health Effects of Grain Foods in Adults
Recruiting
This study will assess the effects of eating whole grain foods versus refined grain foods with different amounts of added sugar. It is hypothesized that a diet including grain products will have beneficial effects on taste hedonics, appetite, food/energy intake, body weight, blood pressure, acute and chronic glycemia and acute and chronic lipemia compared to customary diets controlling for added sugars, saturated fats and sodium.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
07/11/2024
Locations: Purdue University, West Lafayette, Indiana
Conditions: High Whole Grain and Low Sugar, Medium Whole Grain and Low Sugar, Low Whole Grain and Low Sugar, Low Whole Grain and High Sugar
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Recruiting
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
07/08/2024
Locations: Research Site, Carmel, Indiana
Conditions: Erosive Esophagitis
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Michiana Hematology Oncology PC-Crown Point, Crown Point, Indiana
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery
Recruiting
The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Skull Base Neoplasms, Nasal; Hypertrophy, Mucous Membrane (Septum), Cerebrospinal Fluid Leakage
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Parkview Health, Fort Wayne, Indiana
Conditions: Breast Cancer
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/24/2024
Locations: Orthopaedic Associates, Evansville, Indiana
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Evaluation of a Monofocal Intraocular Lens
Recruiting
The aim of this study is to investigate the 3-month visual performance of the CT LUCIA 621P IOL, a hydrophobic aspheric monofocal IOL with a non-constant aspheric optic profile in adult patients 50 years of age or older who are undergoing cataract surgery.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/19/2024
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Cataract
Rehabilitation of Airway Protection in Parkinson's Disease
Recruiting
Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits. The investigators will examine the comparative effectiveness of a novel treatment paradigm delivered in-person versus via telehealth in persons with PD, as well as the role of patient burden and... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
06/12/2024
Locations: Purdue University, West Lafayette, Indiana
Conditions: Parkinson Disease, Dysphagia
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Recruiting
This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/09/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
Recruiting
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana
Conditions: Multiple Sclerosis
Eliminating Monitor Overuse Trial (EMO Trial)
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/03/2024
Locations: Riley Hospital for Children at IU Health, Indianapolis, Indiana
Conditions: Bronchiolitis Acute Viral
A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas
Recruiting
The goal of this clinical trial is to assesses the safety of autologous RD2 Ver.02 as compared to a control for managing transsphincteric and intersphinsteric anal fistulas. The main questions it aims to answer are: Assess the safety and efficacy of RD2 Ver.02 in anal fistula application, compared to control. Complication rate by 6 months of anal fistula treatment with RD2 Ver.02 compared to control. Recurrence of anal fistula at 12 months post-treatment Incidence of perirectal infection by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2024
Locations: Franciscan Health, Indianapolis, Indiana
Conditions: Anal Fistula